


4.20.2023

## Driving Pharma Forward: LENS<sup>ai</sup>'s Distinctive AI Technology for Unrivaled Advancements



**BioStrand's LENS<sup>ai</sup>™ Integrated Intelligence Technology, has been patented, giving the company exclusive access to a technology that could revolutionize the AI industry.** Unlike existing algorithms, LENS<sup>ai</sup> utilizes a unique index, the HYFT™

Index, to sort, analyze, cross-correlate, and organize biological data from any source. This approach produces entirely differentiated outputs, providing access to data, relationships, and perspectives on data information that are not achievable via any other algorithm.

**According to experts,** the unique features of LENS<sup>ai</sup> may be extremely valuable to larger corporations in their AI pursuits, justifying investments that would otherwise not be considered. This technology offers a competitive advantage and the potential to shape the future of the AI industry. Early-stage investors may shift their focus to companies with less immediate public market potential but possess distinctive data outputs and analytical capabilities.

Chamath Palihapitiya, CEO @SocialCapital, predicts that the next wave of technology mergers and acquisitions may involve giants like Google, Microsoft, and Facebook targeting smaller companies with valuable, unique data that can enhance their large language models or other

AI applications. This trend underscores the importance of unique algorithms like LENS<sup>ai</sup> that provide differentiated outputs and can unlock significant value for investors.

LENS<sup>ai</sup>'s differentiated technology could transform large data analysis (DNA, RNA, protein) and significantly alter the competitive landscape of the AI industry. As companies seek to differentiate themselves and gain a competitive advantage, algorithms like LENS<sup>ai</sup> may become increasingly valuable and sought-after.